Skip to Main Content
Padraig O'Suilleabhain, M.D.

Padraig O'Suilleabhain, M.D.

Professor

School
Medical School
Department
Neurology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Joined UT Southwestern: 1998

    Clinical Interests:

    • Parkinson Disease
    • Essential Tremor
    • Normal Pressure Hydrocephalus
    • Dystonia

    Research:

    • Diagnosis and prognosis in NPH hydrocephalus
    • High intensity focused ultrasound for treating movement disorders

    Trainee Education

  • Education
    Medical School
    University of Dublin (1991)
    Internship
    St. James's Hospital (1992), Medicine
    Internship
    Mayo Clinic School of Graduate Medical Education (1993), Medicine
    Residency
    Mayo Clinic School of Graduate Medical Education (1996), Neurology
    Fellowship
    Mayo Clinic School of Graduate Medical Education (1997), Movement Disorders
    Research Fellowship
    Mayo Clinic School of Graduate Medical Education (1998), Neurology
    Other Post Graduate Training
    The University of Texas at Dallas (2015), Health Sector Management
  • Research Interest
    • Magnetoencephalography investigating motor control in normal writing and dystonic writing
    • Neuroprotection / disease modification in Progressive Supranuclear Palsy
    • Normal Pressure Hydrocephalus diagnosis and treatment
    • Parkinson disease pharmacotherapy
  • Publications
    First High Intensity Focused Ultrasound Thalamotomy in a Patient with Cerebral Aneurysms
    Feltrin FS, White A, O'Suilleabhain P, Mckenzie L, Pride L, Shah BR Movement Disorders Clinical Practice 2024 Apr 11 444-446
    Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (Nature Medicine, (2021), 27, 8, (1451-1457), 10.1038/s41591-021-01455-x)
    Author Collaboration PS, Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O’Gorman J, Haeberlein SB, Aiba I, Antonini A, Apetauerova D, Azulay JP, Martinez EB, Bang J, Barone P, Barrett M, Bega D, Berg D, Corrales KB, Bordelon Y, Boxer AL, Brandt M, Brueggemann N, Castelnovo G, Ceravolo R, Chuang R, Chung SJ, Church A, Corvol JC, Cudia P, Dale M, Defebvre L, Drapier S, Driver-Dunckley ED, Ebersbach G, Eggert KM, Ellenbogen A, O’Suilleabhain P Nature medicine 2023 Nov 29 2955-2956
    ELectronic Archimedes spiral Neural Network (ELANN)
    Holcomb JM, Maldjian JA, Xi Y, O'Suilleabhain PE, Louis ED, Shah BR Parkinsonism and Related Disorders 2023 Oct 115
    Stigma and Social Avoidance in Adults with Essential Tremor
    O'Suilleabhain P, Berry DS, Lundervold DA, Turner TH, Tovar M, Louis ED Movement Disorders Clinical Practice 2023 Sep 10 1317-1323
    Improving tremor response to focused ultrasound thalamotomy
    Holcomb JM, Chopra R, Feltrin FS, Elkurd M, El-Nazer R, Mckenzie L, O'suilleabhain P, Maldjian JA, Dauer W, Shah BR Brain Communications 2023 5
    Development of ETStig, a measure for stigma in essential tremor
    O'Suilleabhain P, Tovar M, Shukla AW, Tester NJ, Lundervold DA, Turner TH, Howe-Martin L, Louis ED Parkinsonism and Related Disorders 2022 Nov 104 38-43
    Yet Another Way to Lower Homocysteine: Close the Patent Foramen Ovale
    O'Suilleabhain P Neurology 2021 Jul 97 55-56
    Safety and tolerability of srx246, a vasopressin 1a antagonist, in irritable huntington’s disease patients—a randomized phase 2 clinical trial
    Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O’suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Diana Rosas H, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C Journal of Clinical Medicine 2020 Nov 9 1-14
    Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial
    Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T The Lancet Neurology 2019 Jun 18 549-558
    A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
    McGarry A, McDermott M, Kieburtz K, DeBlieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Alan Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M Neurology 2017 Jan 88 152-159
  • Books

    Featured 

  • Professional Associations/Affiliations
    • American Association of Neurologists
    • American Medical Association
    • Dallas County Medical Society
    • Movement Disorder Society
    • Texas Neurological Society